Kidney Cancer Diagnostics and Therapeutics Market Report 2026

The kidney cancer diagnostics and therapeutics market size has grown strongly in recent years. It will grow from $4.31 billion in 2025 to $4.6 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing incidence of renal cell carcinoma, advancement in imaging and biopsy techniques, established use of targeted therapies, growing awareness of early cancer diagnosis, expansion of oncology treatment centers.

The kidney cancer diagnostics and therapeutics market size is expected to see strong growth in the next few years. It will grow to $6.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to rising adoption of immunotherapy regimens, increasing investment in oncology research, growing use of genomic testing in cancer care, expansion of precision medicine approaches, improving access to advanced cancer diagnostics. Major trends in the forecast period include rising adoption of targeted and immunotherapy treatments, increasing use of advanced imaging for early diagnosis, growing demand for personalized kidney cancer treatment, expansion of biomarker-based diagnostic approaches, improved integration of diagnostics and therapeutics.

The rising incidence of kidney cancer is anticipated to drive the growth of the kidney cancer diagnostics and therapeutics market. Kidney cancer is a disease that develops when normal cells in one or both kidneys undergo abnormal changes and begin to grow uncontrollably, leading to the formation of a mass referred to as a renal cortical tumor. Diagnostics and therapeutics for kidney cancer are essential in the management and treatment of the condition, providing multiple advantages for patients. These solutions support effective disease management by enabling early detection, precise diagnosis, appropriate treatment selection, personalized therapy approaches, and ongoing treatment monitoring. For example, in May 2024, the American Cancer Society, a US-based nonprofit organization focused on cancer research and advocacy, reported that approximately 81,610 new kidney cancer cases were expected to be diagnosed in 2024, with an estimated 14,390 related deaths. As a result, the growing prevalence of kidney cancer is expected to fuel the expansion of the kidney cancer diagnostics and therapeutics market.

Major companies operating in the kidney cancer diagnostics and therapeutics market are concentrating on the development of advanced renal cell carcinoma (RCC) solutions to enhance patient outcomes and deliver innovative treatment options tailored to the specific needs of individuals affected by this complex disease. Ongoing research in renal cell carcinoma (RCC) plays a critical role in kidney cancer diagnostics and therapeutics, as it supports the advancement of novel diagnostic approaches and targeted treatments that enable earlier detection and more personalized care for patients. For example, in December 2023, Merck, a US-based pharmaceutical company, introduced WELIREG (belzutifan), the first hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor approved for adult patients with advanced renal cell carcinoma (RCC) who have previously received PD-1 or PD-L1 inhibitors and VEGF-TKIs. This innovative therapeutic class has demonstrated meaningful clinical benefits, including improved progression-free survival and higher response rates compared with everolimus. The approval of WELIREG marks a significant milestone in the kidney cancer diagnostics and therapeutics market, providing a promising new treatment option for patients with advancing disease.

In May 2023, Telix Pharmaceuticals Limited, an Australia-based biotechnology research company, acquired QSAM Biosciences, Inc. for an undisclosed sum. This acquisition is intended to strengthen Telix’s portfolio in the development of targeted radiopharmaceuticals, especially for oncology applications. By incorporating QSAM’s capabilities and technologies, Telix aims to speed up the development of its novel therapies and broaden its footprint in the precision medicine market. QSAM Biosciences, Inc. is a U.S.-based biotechnology research company.

Major companies operating in the kidney cancer diagnostics and therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co., Ltd., Ipsen S.A., Exelixis Inc., Illumina Inc., QIAGEN N.V., Myriad Genetics Inc., Guardant Health Inc., Invitae Corporation, Bio-Rad Laboratories, Inc., Laboratory Corporation of America Holdings.

North America was the largest region in the kidney cancer diagnostics and therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney cancer diagnostics and therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kidney cancer diagnostics and therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the kidney cancer diagnostics and therapeutics market by increasing costs of imported diagnostic imaging equipment, biopsy devices, and oncology drug manufacturing inputs. Diagnostic segments such as CT scans and biopsy tools, along with targeted and immunotherapy treatments, are most affected, particularly in North America and Europe due to reliance on global supply chains. Hospitals and pharmaceutical laboratories face higher procurement and production expenses, which may influence treatment costs. However, tariffs have also encouraged localized manufacturing, regional sourcing of diagnostic equipment, and strengthened domestic oncology supply chains over the long term.

The kidney cancer diagnostics and therapeutics market research report is one of a series of new reports that provides kidney cancer diagnostics and therapeutics market statistics, including kidney cancer diagnostics and therapeutics industry global market size, regional shares, competitors with a kidney cancer diagnostics and therapeutics market share, detailed kidney cancer diagnostics and therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the kidney cancer diagnostics and therapeutics industry. This kidney cancer diagnostics and therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Kidney cancer diagnostics and therapeutics encompass the range of techniques and treatments used to identify and treat kidney cancer, also referred to as renal cell carcinoma. These approaches focus on detecting the disease, assessing its stage and spread, and delivering suitable treatment options to effectively manage the condition.

The primary types of cancer include clear cell RCC, papillary RCC, chromophobe RCC, urothelial carcinoma, transitional cell carcinoma, and others. Clear cell renal cell carcinoma (RCC) is a form of kidney cancer that represents the largest proportion of kidney cancer cases. RCC is further divided into various subtypes based on the microscopic appearance of the cancer cells. Diagnostics and therapeutic solutions for kidney cancer provide substantial advantages in managing clear cell renal cell carcinoma (RCC), the most prevalent subtype of kidney cancer. Management involves the use of components such as pharmaceuticals and diagnostic tools. Diagnosis is carried out using multiple methods, including biopsy, CT scans, nephro-ureteroscopy, intravenous pyelogram, and ultrasound, while treatment options include targeted therapy, immunotherapy, and chemotherapy. The key end users include hospitals, pharmaceutical laboratories, and genomic laboratories.

The kidney cancer diagnostics and therapeutics market consists of revenues earned by entities by providing kidney cancer diagnostics and therapeutics services such as screening and diagnosis, treatment and therapeutics, radiation therapy, chemotherapy, and surgical interventions services. The market value includes the value of related goods sold by the service provider or included within the service offering. The kidney cancer diagnostics and therapeutics market also includes sales of imaging equipment, biopsy tools, surgical instruments, and supportive care products which are used in providing kidney cancer diagnostics and therapeutics services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.